<DOC>
	<DOC>NCT00129961</DOC>
	<brief_summary>The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.</brief_summary>
	<brief_title>Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Kidney transplant at least 1 year prior Subjects with a functioning renal allograft with calculated glomerular filtration rate (GFR) ≥40mL/min (Nankivell method) and proteinuria ≤500mg/day. Stable on cyclosporine or tacrolimusbased multidrug immunosuppressive regimen History of NMSC within last 3 years History of other cancer within last 3 years NMSC with metastatic disease or more than 20 NMSC lesions in last 12 months Multiple organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>